Patents Assigned to Genentech, Inc.
  • Patent number: 11371999
    Abstract: The description relates to a method and kits for determining the total carbonylation level on a polypeptide.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 28, 2022
    Assignees: University of Kansas, Genentech, Inc.
    Inventors: Anna Mah, Christian Schoeneich, Yi Yang, Di Gao, Lynn A. Gennaro
  • Patent number: 11370838
    Abstract: The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties in the production processes.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: June 28, 2022
    Assignee: GENENTECH, INC.
    Inventors: Jayme Franklin, Xin Xin Lin, Jeffrey Gorrell, Timothy Tully, Matthew Hutchinson, Charity Tucker Bechtel
  • Patent number: 11370833
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 28, 2022
    Assignee: Genentech, Inc.
    Inventors: Lan Le, Brian Connolly
  • Publication number: 20220193077
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1) and an EGFR-inhibitor and methods of using such combination therapies.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 23, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Anne EVANGELISTA, Stephanie Royer JOO, Ting-Kun Mark LIN, Sandhya Vinayak MANDLEKAR, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN
  • Publication number: 20220195020
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.
    Type: Application
    Filed: August 4, 2021
    Publication date: June 23, 2022
    Applicant: GENENTECH, INC.
    Inventors: William Cho, Michel Friesenhahn, Robert Paul, Michael Ward
  • Publication number: 20220195027
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.
    Type: Application
    Filed: March 8, 2022
    Publication date: June 23, 2022
    Applicant: Genentech, Inc.
    Inventors: Rajeshwari Swamy, Julie Hambleton
  • Patent number: 11365197
    Abstract: The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: June 21, 2022
    Assignee: Genentech, Inc.
    Inventors: Chen Mao, Dawen Kou, Po-Chang Chiang
  • Publication number: 20220186314
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: January 20, 2022
    Publication date: June 16, 2022
    Applicant: GENENTECH, INC.
    Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
  • Patent number: 11352431
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 7, 2022
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Patent number: 11353403
    Abstract: A method of inspecting and performing material identification of a contaminant found in a vial may include identifying the presence of the contaminant in a lyophilized medicine within the vial, detaching a portion of the vial to create an enlarged opening in the vial, removing substantially an entire cake of lyophilized medicine through the enlarged opening, and analyzing the contaminant using an atomic emissions spectroscopy (AES) technique such as laser-induced breakdown spectroscopy (LIBS). Systems, fixtures and devices associated with the method are also disclosed.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: June 7, 2022
    Assignee: Genentech, Inc.
    Inventor: Andrew David Norriss
  • Patent number: 11352419
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 7, 2022
    Assignees: AC Immune SA, Genentech. Inc.
    Inventors: Oskar Adolfsson, Kristin Ruth Wildsmith, Marcel Van Der Brug, Andreas Muhs
  • Publication number: 20220169675
    Abstract: The current invention reports a method for purifying an antibody by reducing the content of a host cell protein. The method employs a wash step with a low conductivity aqueous solution in an affinity chromatography.
    Type: Application
    Filed: May 24, 2021
    Publication date: June 2, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Paul MCDONALD, Richard ST. JOHN, Marc Wong, Roberto FALKENSTEIN, Wolfgang KOEHNLEIN, Klaus SCHWENDNER, Bernhard SPENSBERGER, Michael WIEDMANN, Frank ZETTL, Annika KLEINJANS, Carina KOPP, Benjamin TRAN, Ryan ERICKSON
  • Publication number: 20220162286
    Abstract: Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Application
    Filed: July 6, 2021
    Publication date: May 26, 2022
    Applicant: Genentech, Inc.
    Inventors: James GIULIANOTTI, Dorothea E. REILLY, Kieran AURORI, Laura C. SIMMONS
  • Publication number: 20220162318
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 26, 2022
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 11340199
    Abstract: Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)—supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: May 24, 2022
    Assignee: Genentech, Inc.
    Inventors: Cadapakam Venkatramani, Mohammad Al-Sayah
  • Patent number: 11337977
    Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 24, 2022
    Assignee: Genentech, Inc.
    Inventors: Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
  • Publication number: 20220151221
    Abstract: Provided herein are methods of freezing mammalian cells for storage or improving thaw recovery of cell banks comprising freezing mammalian cells in a freezing medium having a pH of 6.7 to 8.5.
    Type: Application
    Filed: October 8, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Angela Meier, Steven J. Meier, Phillip Duffy, Marcia Coyne, Kara Calhoun
  • Publication number: 20220152030
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar, Stuart G. Lutzker
  • Publication number: 20220152029
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR
  • Patent number: 11332507
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 17, 2022
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang